Physician profile
Derek Brown
NPI 1124348842
$1,699.86
in general payments reported to CMS, 2019-2025
24 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $299 · 2021: $302 · 2022: $257 · 2023: $263 · 2024: $220 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $351.24 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.68 | 2020-2025 | Jascayd, Ofev, Spiriva Respimat |
| Astrazeneca Pharmaceuticals Lp | $154.17 | 2019-2025 | Airsupra, Tagrisso, Breztri |
| Genzyme Corporation | $124.50 | 2020-2024 | |
| Grifols USA, LLC | $88.51 | 2021-2024 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $77.35 | 2019-2023 | Opsumit |
| Alexion Pharmaceuticals, INC. | $75.39 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $70.82 | 2019-2021 | |
| Mylan Specialty L.P. | $66.17 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $57.85 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $57.54 | 2019-2024 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $54.69 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.19 | 2021-2022 | |
| Electromed, INC. | $46.13 | 2025 | Smartvest |
| Merck Sharp & Dohme LLC | $41.21 | 2021-2024 | Winrevair |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $32.23 | 2020-2023 | |
| Shionogi INC | $32.03 | 2022 | |
| Janssen Pharmaceuticals, INC | $31.40 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.75 | 2022 | |
| Siemens Medical Solutions USA, INC. | $15.87 | 2021 | |
| Ekos Corporation | $15.21 | 2019 | |
| Pfizer INC. | $14.29 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.94 | 2021 | |
| Shire North American Group INC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.